✦ LIBER ✦

Lymphoma transformation in polycythaemia vera treated with hydroxyurea

✍ Scribed by Tim E. Hawkins; John M. Carter; Kenneth R. Romeril; Sharon R. Jackson; Gerard J. Green

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 130 KB
Volume: 44
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.2830440416

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hyperkalaemia associated with hydroxyure

Hyperkalaemia associated with hydroxyurea in a patient with polycythaemia vera

✍ Srecko Marusic; Nives Gojo-Tomic; Vesna Bacic-Vrca; Velimir Bozikov 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 58 KB

Hodgkin lymphoma in a sickle cell anaemi

Hodgkin lymphoma in a sickle cell anaemia child treated with hydroxyurea

✍ L. Couronné; P. Schneider; M. de Montalembert; C. Dumesnil; A. Lahary; J. P. Van 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 55 KB

Acute myeloid leukemia evolving from pol

Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea

✍ Pulik, Marc; Lionnet, François; Genet, Philippe; Petitdidier, Charlotte; Jary, L 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 2 views

Pruritus secondary to hydroxyurea therap

Pruritus secondary to hydroxyurea therapy in a woman with polycythemia vera

✍ Evan Vosburgh 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 2 views

Mechanism for induction of hydroxyurea r

Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji

✍ Ru Jiang; Jian-Ling Zhang; Yukio Satoh; Takeshi Sairenji 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 1 views

## Abstract Hydroxyurea (HU), as an inhibitor of ribonucleotide reductase (RR) through interaction with the R2 component, has been used in the treatment of malignancies. Recently, therapeutic strategies in Epstein‐Barr Virus (EBV)‐targeted lymphoma have been reported. In order to study the effect o

Leukemogenic risk of hydroxyurea therapy

Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a